Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Industry: Healthcare

Shriners Hospitals Wants Children and Families to “Be Burn Aware”

Leave a comment


News Image

“The most important point to remember is that burns are preventable,” said David Greenhalgh, M.D., chief of burns at Shriners Hospitals for Children — Northern California.


TAMPA, Fla. (PRWEB)

Feb. 2–8, 2020, is Burn Awareness Week. During this time, Shriners Hospitals for Children® launches its annual burn awareness and prevention campaign. Since the 1960s, Shriners Hospitals for Children has been a leader in burn care, research and education — and burn injury prevention is a key component in these efforts.

Burn Awareness Week is Shriners Hospitals for Children’s kickoff of a yearlong educational campaign aimed at burn awareness and prevention. Free educational materials, available via the website beburnaware.org, are designed to be a resource for firefighters, teachers, parents and others concerned with the safety and well-being of children.

Building on the theme “Be Burn Aware,” our focus is on preventing burn injuries in the home, because most preventable burn injuries occur in residences. Homes are the sites of thousands of burn injuries to children every year, including scalds, fire-related injuries, and even electrical burns. Many of these types of incidents may be prevented by implementing some simple safety precautions.

“The most important point to remember is that burns are preventable,” said David Greenhalgh, M.D., chief of burns at Shriners Hospitals for Children — Northern California.

Consequently, educating parents and families about burn injuries is an important part of the mission of Shriners Hospitals for Children.

The burn awareness campaign features two child-friendly characters, Boots and Brewster – a caped, cuddly bear and a googly-eyed teapot – who are featured in activity books for children ages 3-7 and 8-12. The duo leads children through the various rooms of a house, pointing out dangers, and how to easily correct or avoid them. The coloring pages, word searches, cartoons and other activities are designed to grab children’s attention and present the information in a memorable, age-appropriate manner. The campaign also features various tip sheets and fact cards, all available online. Most of the materials are available in French and Spanish.

Shriners Hospitals has also created an animated video, Boots and Brewster: The Burn Awareness Pair, which kids are sure to enjoy. In the video, available on YouTube.com/ShrinersHospitals, Boots and Brewster take viewers on a fun and educational adventure to help them become more burn aware.

“Burn prevention strategies by Shriners Hospitals for Children and other organizations have resulted in a significant reduction in burn injuries in children and adolescents,” said George H. Thompson, M.D., interim chief medical officer of Shriners Hospitals for Children.

Shriners Hospitals for Children encourages everyone concerned with keeping children safe to visit beburnaware.org for helpful burn prevention tips and information on how to order the free materials.

About Shriners Hospitals for Children

Shriners Hospitals for Children is changing lives every day through innovative pediatric specialty care, world-class research and outstanding medical education. Our health care system provides care for children with orthopaedic conditions, burns, spinal cord injuries, and cleft lip and palate, regardless of the families’ ability to pay. Shriners Hospitals for Children is a 501(c)(3) nonprofit organization and relies on the generosity of donors. All donations are tax deductible to the fullest extent permitted by law. For more information, please visit shrinershospitalsforchildren.org.

Contact:

Ashley Ozols

Shriners Hospitals for Children

813-499-4273

aozols@shrinenet.org

Share article on social media or email:

Health

Project HOPE Team in China Readies for Arrival of Over 2 Million Masks and Other Protective Gear Bound for Doctors and Nurses in Wuhan

Leave a comment


Project HOPE

“Working together with MAP International, MedShare, and UPS, we are delivering one of the first large-scale international aid shipments to reach the doctors and nurses in Wuhan,” said Rabih Torbay, President and CEO of Project HOPE.


MILLWOOD, Va. (PRWEB)

As China’s coronavirus cases continue to climb, Project HOPE’s team in China is ramping up to receive the first of several shipments of personal protective equipment destined for doctors and nurses battling the novel coronavirus outbreak.

This first shipment contains more than 2 million respirator masks, 11,000 protective suits, and 280,000 pairs of nitrile gloves donated by MAP International and MedShare. Thanks to in-kind transport from UPS, the supplies are scheduled to arrive in Shanghai on Sunday, February 2. Project HOPE, which has worked in China since 1983, will support delivery of the supplies to Hubei Provincial Center for Disease Control and Prevention and onward to hospitals in Wuhan.

“Working together with MAP International, MedShare, and UPS, we are delivering one of the first large-scale international aid shipments to reach the doctors and nurses in Wuhan,” said Rabih Torbay, President and CEO of Project HOPE. “The skyrocketing demand for personal protective equipment has decimated the stockpiles at many health facilities in China, and this shipment will help shore up supplies in Wuhan so more patients can be safely screened and treated.”

Project HOPE has a long history in Wuhan, having collaborated with Wuhan University for nearly 20 years to establish the HOPE School of Nursing — one of its strongest and longest-running health workforce programs, which has trained thousands of nurses. Many of the nurses trained at the HOPE School of Nursing are now tirelessly working to screen and treat those with flu-like symptoms at hospitals in Wuhan.

Project HOPE is working to facilitate additional airlifts of supplies that will arrive in China in the days to come. Our team in China continues to work in close coordination with local officials to learn additional ways we can support health workers and health systems in areas affected by the new coronavirus outbreak.

For more information on our response to the coronavirus outbreak, visit [http://www.projecthope.org.

Share article on social media or email:

Industry: Healthcare

Litiscape Protects Physicians by Vetting Patients for Litigation Risk

Leave a comment


The founder and CEO of Litiscape, Michael Kamalu.

“My goal is for physicians to be able to perform their job to the best of their ability without fear of vulnerability and exploitation,” Kamalu said. “Litiscape will provide physicians with peace of mind again, while also enabling them to provide the best-informed care for their patients.”


PHOENIX, Ariz. (PRWEB)

Litiscape, a new software company created to protect physicians from frivolous malpractice litigation and financial exploitation, launched this month. By screening for over 1,200 different liability factors in real time, Litiscape provides physicians with information that allows them to both protect themselves and give better care to their patients.

The program’s creator, Michael Kamalu, thought of the concept after his father, a private practice family physician, was hit with his fourth malpractice suit. After months of stress and damage to his practice, he discovered the patient had a long history of filing baseless lawsuits in pursuit of monetary payouts. Utilizing his business and medical school background, Kamalu created Litiscape so that physicians wouldn’t have to be blind to high risk situations and even exploitation. He’s also partnered with malpractice insurance carriers to provide physicians who use their software with a significantly discounted insurance policy, saving them a considerable amount of money.

“Unfortunately, the malpractice system incentivizes frivolous litigation,” Kamalu said. “Less than 15% of claims ever show any evidence of medical error, yet 97% of patient plaintiffs receive monetary payouts. Some people justify it by saying malpractice insurance pays the claims so it doesn’t have any significant effect on physicians, but that couldn’t be further from the truth. Premiums go up, countless hours are wasted, carefully groomed reputation is damaged, and in some cases, careers have been ruined. With Litiscape, we are putting some control back in the hands of physicians so that they can have the peace of mind to focus on what they became a doctor for – to help and to heal.”

Litiscape has a proprietary algorithm that calculates a risk profile based on numerous factors including past litigation history, fraud and criminal records. The software also notifies physicians of potential healthcare-influencing factors such as DUIs, prescription fraud, or drug arrests, even detailing what type of drug was involved such as narcotics, barbiturates, or amphetamines. With this knowledge, a physician can be on the lookout for drug-related symptoms and also be aware of which prescriptions may not be appropriate to prescribe.

“My goal is for physicians to be able to perform their job to the best of their ability without fear of vulnerability and exploitation,” Kamalu said. “Litiscape will provide physicians with peace of mind again, while also enabling them to provide the best-informed care for their patients. We believe it will soon become a new standard in the healthcare industry.”

About Litiscape

Litiscape’s core product is a software that allows physicians to vet prospective patients for potential liabilities – analyzing and weighing over 1,200 distinct background factors in real-time, and categorizing them by litigation risk, financial risk, criminal risk, and healthcare-influencing factors. By pulling from every public record and court database across the country, physicians have access to invaluable insights into everyone they treat. Litiscape is redefining the standard in provider protection and informed care. To learn more, visit http://www.litiscape.com.

Share article on social media or email:

Industry: Healthcare

Immunitor publishes interim results from Phase III trial of oral immunotherapy for liver cancer

Leave a comment


What makes this investigation standing apart from immunotherapeutic approaches in oncology is that it attacks the problem from a new angle not attempted before


VANCOUVER, British Columbia (PRWEB)

Liver cancer, called hepatocellular carcinoma (HCC), occurs each year in more than 800,000 people around the world and about 700,000 die from the disease. HCC is the 5th most common cancer and the 2nd leading cause of cancer deaths. Mongolia firmly occupies the first place among all countries when it comes to incidence of HCC, while China has half of all patients suffering from liver cancer. The incidence of HCC is expected to rise in the United States and across the world, given the increasing prevalence of hepatitis C and B infections, alcohol consumption, NASH, diabetes, toxin exposure and obesity. By the time diagnosis of HCC is made, various surgical interventions or liver transplantation are often not feasible. Conventional systemic chemotherapy such as sorafenib, regorafenib, lenvatinib, and cabozantinib are seldom effective and quite toxic. The FDA has recently approved three antibody-based drugs for HCC indication: nivolumab, pembrolizumab, and ramucirumab. Additional immune interventions from the checkpoint inhibitor family, i.e., durvalumab, atezolizumab, and bevacizumab, as well as tremelimumab, which belongs to the anti-CTLA4 class, are being investigated. Experience has shown that none of the currently approved or experimental HCC drugs are free from adverse side effects and have limited effect in shrinking tumors. While we have witnessed a surge of systemic therapies in recent years, the need for safer and truly effective treatment remains.

The Immunitor study is published in January issue of Hepatoma Research(ClinicalTrials.gov Identifier: NCT02232490). Easy-to-use, once-per-day oral tableted therapeutic vaccine called hepcortespenlisimut-L (V5 or Hepko-V5) was developed by Vancouver-based Immunitor Inc in collaboration with medical team at the National Cancer Center in Mongolia and investigators in the USA, China and Thailand. This trial is continuation of successful 75-patient Phase II trial published in 2017 in the Journal of Hepatocellular Carcinoma. Anti-HCC property of V5 was discovered accidentally ten years ago during clinical use for original primary indications, which are chronic viral hepatitis and liver cirrhosis. V5 has been used by over 30,000 individuals since 2002 and has never been reported of causing any serious adverse reactions. The US FDA granted Hepko-V5 orphan drug designation status in 2014. V5 inherently incorporates all circulating antigens from pooled blood of HCC patients, including tumor unrelated immunogens such as viral hepatitis antigens, microbial antigens such as Mycobacterium TB, and alloantigens, which are not necessarily pathogenic. A version of V5 also known as Tubimod is approved by US FDA for immunotherapy of tuberculosis – most prevalent infectious disease in the world.

“What makes this investigation standing apart from current immunotherapeutic approaches in oncology is that it attacks the problem from a new angle that has not been attempted before. Our goal is to demonstrate that oral allogeneic vaccine delivery induces both the immune activation and at the same time the tolerance, which is the counterintuitive approach against paradigm dominating the field of immuno-oncology,” said Dr Aldar Bourinbaiar – the CEO of Immunitor. “We firmly believe that our approach makes sense since we see drastically higher response rate and unprecedented safety unlike anything published in in the past. Our investigation of hepcortespenlisimut-L is in its early stage and we are sure we will make more surprising discoveries down the road. Besides the profound influence on the immune response, which is expected from cancer vaccines, we see very clear clinical benefits in terms of improved liver function and decrease in tumor marker alphafetoprotein (AFP), which we have shown to be correlated with tumor regression. Indeed, when AFP levels in a patient are back to normal levels the tumor disappears.”

About Immunitor

Canada-based Immunitor is a private biopharmaceutical company with affiliations in USA, Russia, China, Hong Kong, Ukraine, Mongolia and South Africa. Immunitor has developed unique oral delivery platform and is among the top ten leading oral vaccine companies globally. Company has an extensive pipeline of 22 oral immunotherapy products at various stages of development, including many already commercialized. Immunitor’s therapeutic vaccines are made as ordinary appearing tablets or pills stable at room temperature for years. They are broadly split into three clinical categories: infectious diseases, metabolic/ inflammatory/autoimmune disorders and oncology indications (cancers affecting lungs, breast, liver, pancreas, gallbladder ducts, GI tract, kidneys, ovaries, cervix, brain, sarcoma, multiple myeloma, etc. For more information, please write at info@immunitor.com.

Share article on social media or email:

Health

2020 Top Dentists Issue of Healthy Living Magazine Now Available

Leave a comment


2020 Top Dentist’s Edition of Healthy Living Magazine

2020 Top Dentist’s Edition of Healthy Living Magazine


SCOTCH PLAINS, N.J. (PRWEB)

NJ Top Dentists has just released the latest Top Dentists issue of Healthy Living Magazine which features all 985 reviewed and approved New Jersey Top Dentists for 2020.

NJ Top Dentists is an exclusive healthcare resource that reviews healthcare providers in the state of New Jersey based on merit, not popularity. Each provider is put through a rigorous application and review process that includes but is not limited it, a minimum of 5 years in practice, a clean license, no significant malpractice issues, and generally stellar patient reviews. To view all reviewed and approved 2020 NJ Top Dentists, please turn to page 52 in the digital edition. To learn more about our methodology please visit our Review process.

All providers are reviewed at no cost to them and if approved listed in the magazine directory as an approved provider also at no cost to them. We also offer the magazine free to the public via direct in home distribution (across all 21 counties of New Jersey) and free subscriptions. You can click here to subscribe to Healthy Living Magazine for free and the next issue will be delivered to your doorstep. If you prefer to read the latest issue digitally, you can do so here.

The newly released issue also features fun-to-read articles on tools to keep your pet’s teeth squeaky clean, snow day recipes, eco-friendly dental options and more.

The goal of NJ Top Dentists’ magazine, Healthy Living is to provide New Jersey residents with a complete informational resource to assist them in choosing a local highly qualified healthcare provider at no cost. To take a look at all past and present Healthy Living issues, please click here.

Don’t forget to subscribe to receive a no cost printed copy of the next issue of Healthy Living featuring all NJ Top Doctors & Dentists which comes out in the Fall of 2020.

About Us

NJ Top Dentists is a division of NJ Top Docs. NJ Top Docs is a comprehensive, trusted and exclusive healthcare resource featuring reviewed and approved Top Doctors and Dentists in New Jersey online in an easy to use format. NJ Top Docs only reviews and approves providers based on merit after they have been extensively vetted.

NJ Top Docs is a division of USA Top Docs which allows patients to meet providers online before making their appointment.

For more information, please click here to contact us or visit http://www.NJTopDocs.com.

You can also follow us on Facebook, Twitter, & Instagram.

Share article on social media or email:



Industry: Healthcare

Immunitor unveils breakthrough immunotherapy to treat tuberculosis in as short as one month

Leave a comment


This is first-ever TB vaccine available as a low-cost pill


VANCOUVER, British Columbia (PRWEB)

Immunitor Inc., commercial-stage biotech company, is pleased to announce the publication of positive results from the randomized, placebo-controlled Phase III clinical trial for Tubivac (V7), the first-in-class, orally-available therapeutic vaccine used as an immune adjunct for the chemotherapy of tuberculosis (TB). Tubivac consists of inactivated non-pathogenic strain of Mycobacterium vaccae, which is related to Mycobacterium tuberculosis – the pathogen that causes tuberculosis – most prevalent infectious disease affecting 10 million people every year. In addition, approximately 2 billion people, equivalent to roughly one quarter of the global population, are estimated to harbor a latent TB infection and therefore at risk of progressing to overt tuberculosis. The global spread of multi-drug-resistant (MDR) strains and co-infection with HIV also contributes to the challenges of treating TB – top infection in the world that killed 1.5 million people in 2018. The daily pill of Tubivac taken along with standard TB drugs has cleared TB bacteria within one month – the shortest treatment course available today. Currently, 6 months is required to treat drug-sensitive TB and at least 12 months for MDR-TB, which benefits 85% and 50% of patients respectively – the rates Tubivac can achieve after just one month.

The published trial confirmed safety and efficacy of two earlier Phase II studies of V7 at same 10 microgram per dosage strength. “This is first-ever TB vaccine available as a low-cost pill”, said Dr. Aldar Bourinbaiar, CEO of Immunitor. “Tubivac is a result of our earnest effort to address the unmet need for faster-acting regimens to treat all forms of tuberculosis including drug-resistant TB and TB with HIV. The anti-TB property of Mycobacterium vaccae strain used in this trial was first discovered in 1972 by Cynthia and John Stanford during Buruli ulcer outbreak in Uganda. The positive data from our trial, published in Elsevier’s Journal of Clinical Tuberculosis and Other Mycobacterial Diseases is a culmination of 10 years of altruistic endeavor aimed at developing oral immunotherapy with a novel mechanism of action that can alleviate suffering of people with TB. Our study has shown that Tubivac helps gain weight, reduce inflammation, and can counteract hepatotoxicity commonly caused by TB drugs. In addition, our clinical experience shows that Tubivac has a potential to treat asthma, emphysema, COPD, lung cancer and fibrosis – other serious medical conditions affecting lungs. Nothing principally new, since introduction of BCG vaccine in 1921 and deployment of TB antibiotics from 1940’s, has been developed to eradicate TB, which remains the number one killer disease today. Tubivac is faster, safer and cheaper of any TB interventions introduced so far and poised to be the paradigm shifter.”

About Immunitor

Canada-based Immunitor is a private biopharmaceutical company with affiliations in USA, Russia, China, Hong Kong, Ukraine, Mongolia and South Africa. Immunitor has developed unique oral delivery platform and is among top ten oral vaccine companies globally. Company has an extensive pipeline of twenty two oral immunotherapy products at various stages of development, including several already commercialized. Immunitor’s therapeutic vaccines are made as ordinary appearing pills stable at room temperature for years. They are broadly split into three clinical categories: infectious diseases; viral, bacterial, fungal and protozoan, metabolic/autoimmune/inflammatory disorders; atherosclerosis, diabetes, obesity, hypertension, psoriasis, endometriosis, etc. and oncology indications, e.g., cancers affecting lungs, breast, liver, pancreas, gallbladder ducts, GI tract, kidneys, ovaries, cervix, brain, multiple myeloma, etc. The development of three products was supported by Global Grand Challenges initiative from Bill and Melinda Gates Foundation, financed by the government of Canada. Immunitor currently offers for sale Ukrainian-made Immunoxel (Dzherelo) – immunomodulating phytoconcentrate and in-house developed Tubimod (V5), both of which were shown in Phase III trials to reduce the duration of TB treatment down to one month. Tubivac (V7) is yet another proprietary, orally formulated anti-TB orphan drug with shorter treatment duration. The injectable form of M. vaccae has been through over hundred clinical trials in more than 20 countries since 1980’s – however this inconvenient-to-use formula is twice-less effective and sold in China under VACCAE trademark by Anhui Zhifei Longcom – a company that has been inspired by John Stanford’s pioneering work. For more information, please write at info@immunitor.com.

Share article on social media or email:

Health

Thornberry’s NDoc® EMR ranked #1 again!

Leave a comment


Thornberry and 7 KLAS logos - 2020

Thornberry has been ranked #1 since 2013

Seven years in a row! We are both humbled and thrilled to be top-ranked by KLAS again this year.


LANCASTER, Pa. (PRWEB)

Thornberry Ltd has been rated #1 by customers once again, making it seven in a row for the company’s NDoc® home health and hospice EMR.

Thornberry first set the record in 2017 with a fourth consecutive “Best in KLAS” award for the homecare segment, and it continues to leave the competition behind. Thornberry’s home health and hospice EMR received a top-ranked score of 90.4 in the 2020 Best in KLAS: Software & Services report, surpassing the average for the segment by more than nine points.

This year, NDoc won the KLAS Category Leader award for the new Home Health & Hospice (Small) market segment. While not an official competitor in the new “large” market because NDoc data is limited for that segment, Thornberry scored the highest in either category, keeping them ahead of the competition for the seventh year in a row.

“Seven years in a row! We are both humbled and thrilled to be top-ranked by KLAS again this year,” said Thornberry President and CEO Tom Peth, “and we’d like to thank our providers once again. We couldn’t be #1 year after year without their loyal partnership and support, which in turn would not be possible without the dedication and hard work of our Thornberry team.” Peth continued, “We continue to take pride in providing innovative technology and top-level service; this award lets us know we’re doing a lot of things right and how to continue our commitment to the growth and success of our customers.”

KLAS winners are determined through extensive surveys and interviews with healthcare providers on the efficiency and quality of health IT products. KLAS Research methodology evaluates and ranks vendors in six key categories: Culture, Product, Relationship, Operations, Loyalty, and Value. Once again, Thornberry received A ratings in more categories than any other vendor. “I can’t say enough about the service and response that we get from Thornberry,” commented one Director in October 2019. “Thornberry’s responsiveness really sets them apart… NDoc seems to be light-years ahead of other products. Thornberry’s service is second to none.” Clinical users agree. In December 2019 a Nurse user commented: “The support is unbeatable; it is above and beyond anything I have ever seen.”

The Best in KLAS and Category Leader designations are a recognition of outstanding efforts to help healthcare organizations in their quest to deliver quality patient care. Category Leader awards are offered in new segments with a focused impact across many health systems. “Providers and payers demand better performance, usability, and interoperability from their vendor partners every year,” says KLAS President Adam Gale. A KLAS award sets the standard of excellence in a market segment, Gale adds: “It serves as a signal to providers that they should expect only the best from the winning vendors.”

Thornberry will be recognized for its record-breaking win at the annual Best in KLAS awards reception at HIMSS on March 9 in Orlando, FL.

About Thornberry

In the 27 years since its founding, Thornberry has become an innovative and respected leader in both certification and interoperability, providing a complete suite of innovative tools for homecare and hospice through its NDoc® software solution. Top-ranked by KLAS for the seventh year in a row, NDoc is a CCHIT Certified Long Term and Post-Acute Care (LTPAC) EMR additionally certified for Home Health. Learn more about the powerful, flexible, and comprehensive NDoc solution at ndocsoftware.com.

About KLAS

KLAS is a data-driven company on a mission to improve the world’s healthcare by enabling provider and payer voices to be heard and counted. Working with thousands of healthcare professionals, KLAS collects insights on software, services and medical equipment to deliver reports, trending data and statistical overviews. KLAS data is accurate, honest and impartial. The research directly reflects the voice of healthcare professionals and acts as a catalyst for improving vendor performance. To learn more about KLAS and the insights we provide, visit KLASresearch.com.

Share article on social media or email:

Industry: Healthcare

Cieplak Dental Excellence Attends ActDental Course to Improve Quality of Dental Care in La Plata, MD

Leave a comment


La Plata, MD Dentist, Dr. Patrick Cieplak, and His Team at Cieplak Dental Excellence

Cieplak Dental Excellence Attends “The Successful Dental Practice” from ActDental

I couldn’t be happier with my nice smile. My teeth feel great!


LA PLATA, Md. (PRWEB)

Dr. Patrick Cieplak and his team recently attended a continuing education course from ActDental to better serve their patients. The course, titled “The Successful Dental Practice,” will help Cieplak Dental Excellence provide more innovative and personalized services like smile makeovers, dental crowns, and full mouth dental implants in La Plata, MD.

Cieplak Dental Excellence has been serving the La Plata, MD community for over 30 years, providing comprehensive dental services using the latest dental technology. Dr. Cieplak and his team regularly attend continuing education seminars to remain up-to-date in dentistry and to provide the most advanced treatments for their patients. Cieplak Dental Excellence has had many satisfied patients over the years.

“I had very bad teeth as a kid,” says Peter, a patient of Dr. Cieplak. “I got dental implants and dental crowns. Now, I couldn’t be happier with my nice smile. My teeth feel great!”

During the seminar, the team gained insight on how to grow their practice by differentiating themselves from organized dentistry. They also learned how to attract more patients to their practice and reduce cancellations. Improving how effectively the team can offer dental services will ultimately improve the overall experience of existing and new patients.

Cieplak Dental Excellence is proud to offer such services as dental crowns, smile makeovers, and full mouth dental implants. A smile makeover is a personalized treatment involving one or more procedures to restore the health, function, and cosmetic look of teeth. Treatment can include dental crowns or porcelain veneers to improve the shape, size, and color of teeth. Smile makeovers can also include the restoration of a full set of hopeless or missing teeth using full mouth dental implants. Dr. Cieplak and his team routinely provide custom smile makeover treatments to return their patients to a state of health, function, and confidence.

Dr. Cieplak welcomes patients to experience innovative and personalized dental care at Cieplak Dental Excellence. Those interested in dental crowns, full mouth dental implants, and other advanced dentistry treatments in La Plata, MD can contact the practice by calling 301-609-9999 or visiting http://www.patcieplakdds.com.

About the Practice         

Cieplak Dental Excellence has been offering trusted dental care to patients in the La Plata, MD area for over 30 years. Founder, Dr. Patrick Cieplak, is dedicated to learning the latest dental techniques and has completed thousands of hours of continuing education courses. Dr. Cieplak is one of only 3,000 dentists worldwide to achieve Mastership with the Academy of General Dentistry. He is a Fellow in the International Congress of Oral Implantology as well as Associate Fellow in the American Academy of Implant Dentistry. His associate, Dr. Charniece Whitaker, is a general dentist who received her Doctor of Dental Surgery degree from the University of Maryland School of Dentistry. She strives to always develop her skills and serve her community with minimally invasive and effective techniques. To learn more about Dr. Cieplak, Dr. Whitaker, their team or the services they offer, please visit http://www.patcieplakdds.com or call 301-609-9999 to schedule an appointment.

Share article on social media or email:

Health

Shady Grove Fertility (SGF) Expands Northern Virginia Physician Team and Welcomes Nicole Doyle, M.D., Ph.D., Improving Access to Quality, Affordable Fertility Care

Leave a comment


Dr. Nicole P. Doyle joins Shady Grove Fertility’s Northern Virginia Medical Team.

I firmly believe that the essence of practicing good medicine lies in genuine desire and devotion to delivering the highest quality of medical care through knowledge, strong clinical judgment, compassion, and dedicated support of the patient.


WASHINGTON (PRWEB)

Shady Grove Fertility (SGF) is proud to welcome Nicole P. Doyle, M.D., Ph.D., FACOG, to the Northern Virginia Medical Team. Dr. Doyle will begin seeing patients in SGF’s Fairfax, VA location in February 2020, and will provide a full range of state-of-the-art, in-house diagnostic and treatment options for female and male infertility, elective egg freezing, LGBTQ family building, and fertility preservation prior to cancer treatment.

Dr. Doyle earned her medical degree and doctorate in philosophy from the Medical School of the Technical University of Munich and completed her residency training in Obstetrics and Gynecology at Georgetown University Hospital. Dr. Doyle completed her fellowship in Reproductive Endocrinology and Infertility at the National Institutes of Health.

“Both institutes where I studied send their students to SGF to be trained so I had the unique opportunity to obtain an inside perspective of the philosophy and mechanics that drive the accomplishments of SGF. I firmly believe that the essence of practicing good medicine lies in genuine desire and devotion to delivering the highest quality of medical care through knowledge, strong clinical judgment, compassion, and dedicated support of the patient. This is the fundamental base that allows us to excel at what we do every day. Early on in my training, it was obvious to me that SGF stands for these qualities and that the achievements of the practice were the result of dedication and hard work by many. I wanted to be a part of their team ever since,” shares Doyle.

Dr. Doyle has published several peer-reviewed scientific manuscripts, book chapters, and review articles in many leading scientific journals in the fields of reproductive endocrinology and infertility. Her specific research interest is examining the timing for embryo transfer and she continues this work as a member of the research team at Shady Grove Fertility. She is a fellow of the American Congress of Obstetrics and Gynecology and a member of numerous medical organizations.

Her clinical interests include any aspect of female and male infertility, in particular optimizing outcomes in patients with diminished ovarian reserve or premature ovarian insufficiency; making advances in in vitro fertilization, oocyte donation, recurrent pregnancy loss, fertility preservation, and polycystic ovary syndrome (PCOS).

When asked about her approach to caring for patients, “Honesty, thorough counseling, transparence, empathy, and attentive listening have always worked for my patients and me. There is no one approach for a struggling patient, but rather a personalized strategy for each patient at each step of the way. For some a gentle push is needed, for others stopping or a break from treatment might be indicated. A solid physician-patient rapport is the basis to finding the right solution for every patient,” shares Doyle.

SGF has had a significant presence in Northern Virginia for over 2 decades and is the largest fertility center in the state with 13 reproductive endocrinologists and 1 reproductive urologist, 7 locations in Northern Virginia, two locations in Richmond, VA., and two state-of-the-art IVF centers located in Fairfax, VA, and Richmond, VA.

To schedule an appointment with Dr. Nicole Doyle or any other SGF physician, please call the SGF New Patient Center at 1-888-761-1967 or submit this brief online form.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 38 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

Share article on social media or email:

Industry: Healthcare

FocalPoint Holdings Builds Patient Experience Expertise with Addition of Shareef Mahdavi and SM2 Strategic

Leave a comment


“FocalPoint’s skill sets complement the work we’ve been doing with clients. They are bringing together best-of-class experts and I’m proud to be part of the group.” – Shareef Mahdavi


FREEHOLD, N.J. (PRWEB)

FocalPoint Holdings, one of the leading ophthalmic investment, management and technology firms, is pleased to welcome Shareef Mahdavi to their team, bringing deep expertise in helping clients improve the customer experience in medical environments. This addition to the FocalPoint portfolio gives clients access to one of the foremost thought leaders in this area. “I’ve had the privilege over the years of working with many practices and device manufacturers. The technology available to doctors for their patients is incredible,” noted Mahdavi. “What’s been missing is an experience that makes patients want to spend more time and money at the practice. This is especially critical in self-pay elective services, a large growth opportunity for modern medical practices.”

Earlier in his career, Mahdavi led the U.S. marketing launch for laser manufacturer VISX, helping LASIK become the top-performed elective surgical procedure in the US and Worldwide. Adding to his marketing and sales background, he became a Certified Expert in “The Experience Economy,” teaching clients how to create more value by differentiating their practices with a superior customer experience. His new book, “Beyond Bedside Manner: Insights on Perfecting the Patient Experience” will be launched in April by Story Seven Publishing.

“Shareef has always been a thought leader in the ophthalmic industry, and having him on our team seemed like a natural fit. The patient experience is so important for our practices and partners, and having someone of his caliber in our firm is something we are extremely excited about. We want FocalPoint to have the best and brightest innovators in our firm, and his addition continues that tradition,” said Dr. Anish Kapur, President of FocalPoint Holdings.

“FocalPoint’s skill sets complement the work we’ve been doing with clients,” added Mahdavi. “They are bringing together best-of-class experts and I’m proud to be part of the group.”

For more information on how FocalPoint Holdings can help improve your ophthalmology or optometry practice’s efficiency and revenue, please contact us at info@focalpointholdings.com today.

About FocalPoint Holdings

FocalPoint Holdings is a privately held investment and management firm specializing in healthcare and technology companies. As an experienced partner to outstanding management teams, FocalPoint helps build durable companies with sustainable value, especially within the ophthalmic industry. With their team’s depth of knowledge in multiple industries, FocalPoint is the perfect partner for entrepreneurs and business executives looking to grow their business.

Additional information about Focal Point Holdings is available at https://linkedin.com/company/focalpointholdings and http://www.focalpointholdings.com.

Share article on social media or email: